Corteva, Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Corteva (CTVA) Stock After Recent Pullback Is The DCF Upside Still Intact - simplywall.st

AI-generated analysis

📉 Corteva shares have recently eased slightly, trading around $75.71 after a 7.9% pullback over the last week.

📈 Long-term performance remains strong with a 36.7% return over three years and an 84.1% gain over five years.

💰 The company generated trailing twelve-month free cash flow of approximately $2.03 billion.

🔮 DCF projections estimate annual free cash flows will reach about $3.89 billion by the year 2035.

💵 A Discounted Cash Flow model calculates an intrinsic value of $107.17 per share, implying a 29.4% undervaluation.

📊 Corteva currently trades at a P/E ratio of 40.44x, which is higher than its proprietary Fair Ratio of 25.49x.

🏭 The stock's P/E sits above the Chemicals industry average of roughly 28.77x but below the peer group average of 53.67x.

🧠 Simply Wall St introduces a 'Narrative' approach to valuation that allows investors to model different growth scenarios against current prices.

📉 The article notes that Corteva's 1-year return is lagging behind its peers despite the DCF suggesting value.

Bullish Signals
  • The stock is estimated to be undervalued by approximately 29.4% based on a Discounted Cash Flow analysis projecting an intrinsic value of $107.17.
  • Corteva has demonstrated strong long-term growth with a 36.7% return over the past three years and an 84.1% return over five years.
  • The company maintains a healthy cash generation profile with trailing twelve-month free cash flow of $2.03 billion.
  • Future cash flow projections are robust, with estimates reaching $3.89 billion by 2035 according to the model used.
  • Corteva's P/E ratio of 40.44x is lower than its peer group average of 53.67x, suggesting it may be relatively cheaper compared to direct competitors.
Risk Factors
  • The stock trades at a P/E ratio of 40.44x, which is significantly higher than the company's proprietary Fair Ratio estimate of 25.49x.
  • Corteva's current valuation multiple exceeds the Chemicals industry average of roughly 28.77x, indicating potential overvaluation on traditional metrics.
  • The recent share price has declined by 11.7% year-to-date and 7.9% in the last week, reflecting a short-term pullback.
Full Analysis
Corteva (CTVA) stock has recently pulled back, trading around $75.71 per share after a 7.9% decline over the past week and an 11.7% drop year-to-date. Despite this short-term weakness, the stock remains up 3.0% over the last year and has delivered significant long-term returns of 36.7% over three years and 84.1% over five years. The article analyzes whether this pullback represents a buying opportunity or a shift in risk perception within the chemicals sector. A primary valuation metric used is the Discounted Cash Flow (DCF) model, which projects Corteva's future free cash flows out to 2035. Based on trailing twelve-month free cash flow of approximately $2.03 billion and analyst extrapolations reaching $3.89 billion by 2035, the model calculates an intrinsic value of $107.17 per share. This suggests the stock is undervalued by roughly 29.4% relative to its current price. However, traditional P/E ratio analysis presents a conflicting view. Corteva currently trades at a P/E of 40.44x, which is higher than its proprietary 'Fair Ratio' estimate of 25.49x and above the Chemicals industry average of 28.77x. While this metric indicates the stock might be overvalued on a multiple basis, the article suggests that narrative-based valuation approaches allow investors to reconcile these differing signals by attaching their own growth stories to the financial forecasts.